Cellular infusion is one of the most marketed terms in regenerative medicine, and also one of the most misunderstood. It is often introduced to patients as a single category, sold under a long list of names, and described as a simple path to repair. In practice, cellular infusion is not one thing. It is a family of treatments with several distinct types, each built from a different cell source, processed in a different way, and matched to a different clinical problem.

What Is Cellular Infusion?

A cellular infusion is a treatment in which a measured product made of living cells is delivered into the bloodstream through an intravenous line. The patient sits in a clinic chair or hospital bed, a soft tube is placed in the arm, and the product drips in over a defined period of time. The format looks like any other IV.

What distinguishes a cellular infusion from a drug infusion is what is in the bag. A standard IV medication is a chemical compound dissolved in fluid. A cellular infusion contains living cells suspended in a carrier solution. Those cells then travel through the bloodstream and interact with the body in a way a small molecule cannot.

Beyond that shared format, cellular infusions split into several distinct types based on where the cells come from and what the product is designed to do. Two infusions can both be called cellular therapy and still be very different treatments.

The Main Types of Cellular Infusion

Bone marrow infusion. The oldest form of cellular infusion. The cells are drawn from bone marrow and used to rebuild a patient's blood and immune system. This is the category behind bone marrow transplants for leukemia, lymphoma, and related blood diseases.

Cord blood infusion. Cells collected from the umbilical cord after a healthy birth, banked, and matched to a recipient. Used for many of the same blood and immune conditions as bone marrow, especially when a matched adult donor cannot be found.

Mesenchymal cell infusion. A different type of cell, harvested from bone marrow, fat (adipose tissue), or perivascular tissue (the layer along the outside of blood vessels). These cells do not rebuild blood. They are used to support the body's response to inflammation and injury, with programs aimed at orthopedic conditions, autoimmune disease, and other inflammatory problems. The source matters: a product from adipose tissue is not the same as one from perivascular tissue.

Birth tissue products (amnion, Wharton's jelly). Products derived from birth tissue. Often marketed for joint, wound, and orthopedic use. Some preserve living cells. Many are dehydrated or otherwise processed in ways that leave few or no living cells in the final unit, despite the cellular label.

Engineered immune cell infusion (CAR T). A patient's own immune cells are removed, modified in a laboratory to recognize a specific target, and infused back. Approved for several blood cancers.

"Cellular infusion" by itself does not tell a patient which of these they are receiving, and the right type depends on the condition being treated. The evidence is also uneven across the field. Bone marrow and CAR T infusions have decades of clinical record behind them. Mesenchymal and birth tissue programs vary widely in oversight and results, and marketing language often blurs that line. Cardiac efforts in particular, including in heart failure and post infarction recovery, have so far produced mixed and largely investigational outcomes.

Why Most Cellular Infusions Are Not Designed for AFib or CHF

Atrial fibrillation and congestive heart failure are not blood diseases, joint problems, or generic anti-aging complaints. They are rhythm and pump disorders driven, in many patients, by inflammation along the nerves that signal the heart. A general purpose cellular infusion is not built for that target. Several practical points set the boundary:

The cell source matters. Bone marrow, cord blood, adipose tissue, amnion, and perivascular tissue are not interchangeable. A product designed for orthopedic use is not the same product as one designed to support nerve and cardiac tissue.

Processing changes what is in the bag. Some workflows preserve viable cells with documented counts. Others rely on dehydrated, lyophilized, or otherwise processed tissue that contains few or no living cells by the time it reaches the patient. A patient told they are receiving a cellular infusion should know whether the final unit is actually a live cell product.

Cell counts and viability are not always reported. Some programs release each unit with recorded total nucleated cells, total cells, and live cell viability. Others do not. A patient cannot verify what is in the bag beyond the label claim unless those numbers are provided.

Approved uses are narrower than marketing suggests. The FDA regulates many cellular products under 21 CFR Part 1271, and the agency has issued public warnings and warning letters about clinics marketing unapproved infusions for chronic disease. A patient should know which framework applies to a given program.

Travel based programs carry oversight risk. A meaningful share of patients pursuing cellular infusion still travel overseas for products that are not available in the United States. Those trips are often expensive, emotionally difficult, and carried out with limited follow up if a complication appears at home.

For AFib and CHF specifically, the shared driver, inflammation along the cardiac nerves, is what defines the design problem. A cellular infusion built for a different problem is not built to address it.

A New Frontier: Kaorta

Kaorta® is the only U.S. based patented cell therapy protocol developed for atrial fibrillation and congestive heart failure. Both conditions share a root driver: inflammation along the nerves that tell the heart when to beat. Kaorta® is designed to work on that layer.

The approach started in our neuropathy practice, where the same cells were used to support recovery around inflamed nerves in the brain. After nine years of developing the PVC method, we recognized the same kind of inflammation behind AFib and CHF, sitting on the nerves that signal the heart. The first AFib patient was treated in 2023 and has lived a normal life since.

A treatment cycle begins with tissue donated by the patient or a related donor and collected by a plastic surgeon. The harvest is developed into PVC (perivascular) cells through a patented process carried out inside an FDA registered laboratory, with the patent and the laboratory held by separate entities. On treatment day, the cells are delivered through a single IV infusion in a clinic setting. The patient sits in a chair, the bag drips in, and the patient goes home the same day.

Several points set the Kaorta® program apart from many cellular infusion offerings:

• Built for AFib and CHF. The protocol is designed for two specific conditions that share a common driver, rather than positioned as a general purpose infusion.
• Live cells in the final product. Kaorta® is built around the perivascular fraction and delivered as a live cell product, not a dehydrated or acellular preparation.
• Documented cell counts. A typical Kaorta® unit carries 30 to 90 million cells, and each unit is released with recorded total nucleated cells, total cells, and live cell viability, typically reported between 95% and 100%.
• U.S. based and physician led. The protocol is delivered inside a controlled clinical setting in the United States, with no requirement for travel overseas.
• Inside the FDA framework. The therapy follows rigorous protocols and complies with FDA guidelines outlined in 21 CFR 1271.10, which define oversight under section 361 of the PHS Act and 21 CFR Part 1271.

The PVC cells help the body reduce the inflammation along the nerves that signal the heart. As that inflammation comes down, the nerves have room to recover and the rhythm has a chance to steady. Kaorta® is not a replacement for a cardiologist's plan. It is a different layer of the same condition.

Sources

• U.S. Food and Drug Administration. "21 CFR Part 1271: Human Cells, Tissues, and Cellular and Tissue Based Products."
• U.S. Food and Drug Administration. "Important Patient and Consumer Information About Regenerative Medicine Therapies."
• U.S. Food and Drug Administration. "Approved Cellular and Gene Therapy Products."